Clinical Studies

Title PI / Site PI Agency
A Multicenter, Randomized, Parallel-group, Double-blind, Two-arm, Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive with Systemic Sclerosis Mayes Astrazeneca
Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Evaluate the Efficacy, Safety and Tolerability of Efzofitimod in Patients With Systemic Sclerosis Related Interstitial Lung Disease Mayes aTyr Pharma
A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with early progressive diffuse cutaneous systemic sclerosis Mayes Boehringer Ingelheim Pharmaceuticals
A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD) Mayes Prometheus Biosciences (now Merck)
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Trial Evaluating the Safety and Efficacy of Investigational Products in Patients with Interstitial Lung Disease Secondary to Systemic Sclerosis (CONQUEST) McMahan SRF/ Medpace Clinical Research
Interrogating the pathophysiological mechanisms of constipation in patients with systemic sclerosis McMahan NIH
Molecular Profiling of Spinal Disease Progression in Ankylosing Spondylitis Hwang NIH
A randomized placebo-controlled, double blind phase 2 clinical trial of memantine for the treatment of cognitive impairment in systemic lupus erythematosus Subash VUMC Clear Memory
A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease Hwang Janssen Research & Development